EDITORIALS

Preserving the Sacred Bond: An Audit Must Be Performed

Bruce A. Chabner
The Oncologist 2008; 13: 922; doi:10.1634/theoncologist.2008-0179
[Full Text] [PDF]  

SUMMARY: In light of additional questions raised in the Letters to the Editor section of this issue regarding results of the International Early Lung Cancer Action Program clinical trial on computed tomography screening for lung cancer, Editor-in-Chief of The Oncologist, Bruce A. Chabner, M.D., in this editorial calls for a thorough, complete, and impartial audit of this trial.

One in Five Cancer Clinical Trials Is Published: A Terrible Symptom—What's the Diagnosis?

Gregory A. Curt, Bruce A. Chabner
The Oncologist 2008; 13: 923-924; doi:10.1634/theoncologist.2008-0174
[Full Text] [PDF]  

SUMMARY: This editorial invites readers to weigh in on whether The Oncologist should expend the considerable effort and expense to produce a peer-reviewed, searchable venue for publishing the results of all well-executed cancer trials that fail to meet positive endpoints.

Commentary: Practicing on the Tip of an Information Iceberg? Evidence of Underpublication of Registered Clinical Trials in Oncology

Scott Ramsey, John Scoggins
The Oncologist 2008; 13: 925-929; doi:10.1634/theoncologist.2008-0133
[Abstract] [Full Text] [PDF]  

SUMMARY: The authors evaluated the proportion of ClinicalTrials.gov registered trials that are published in the peer-reviewed literature. Only a minority of clinical studies in cancer registered with ClinicalTrials.gov were published in peer-reviewed and other widely accessible journals, raising concern about the completeness of the available information on present and future cancer treatments.

Commentary: Publishing Cancer Clinical Trial Results: A Scientific and Ethical Imperative

James H. Doroshow
The Oncologist 2008; 13: 930-932; doi:10.1634/theoncologist.2008-0168
[Full Text] [PDF]  

SUMMARY: This editorial further discusses the low number of oncologic clinical trials published in the peer-reviewed literature and reports on the development by the National Cancer Institute of its own clinical trials database to capture all administrative and outcomes data for all clinical studies performed at National Cancer Institute–supported institutions.

Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?

Thomas E. Stinchcombe, Mark A. Socinski
The Oncologist 2008; 13: 933-944; doi:10.1634/theoncologist.2008-0019
[Abstract] [Full Text] [PDF]  

SUMMARY: The use of gefitinib was restricted in the U.S. after the results of a trial showed no significant benefit in overall survival with this treatment. However, results of recent gefitinib trials have been provocative, and suggest a role for gefitinib in the treatment of advanced NSCLC.

Consensus Conference: Multimodality Management of Early- and Intermediate-Stage Non-Small Cell Lung Cancer

Rodolfo Bordoni
The Oncologist 2008; 13: 945-953; doi:10.1634/theoncologist.2008-0062
[Abstract] [Full Text] [PDF]  

SUMMARY: Presented are the conclusions of a consensus conference of leading experts in the non-small cell lung cancer field, held at the 5th Annual Atlanta Lung Cancer Symposium on October 25–27, 2007, to provide the oncology community with direction on how overall outcomes can be improved.

The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy

Xuhui Zhou, Weiguo Hu, Xuebin Qin
The Oncologist 2008; 13: 954-966; doi:10.1634/theoncologist.2008-0089
[Abstract] [Full Text] [PDF]  

SUMMARY: The mechanism of action of and resistance to rituximab therapy in B-cell non-Hodgkin's lymphoma, in particular, the involvement of the complement system, are extensively reviewed.

Neoplastic Meningitis

Marc C. Chamberlain
The Oncologist 2008; 13: 967-977; doi:10.1634/theoncologist.2008-0138
[Abstract] [Full Text] [PDF]  

SUMMARY: This review summarizes the epidemiology, diagnosis, and treatment of neoplastic meningitis.

Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors

Ahmed Idbaih, François Ducray, Monica Sierra Del Rio, Khê Hoang-Xuan, Jean-Yves Delattre
The Oncologist 2008; 13: 978-992; doi:10.1634/theoncologist.2008-0056
[Abstract] [Full Text] [PDF]  

SUMMARY: This paper reviews the main studies evaluating targeted therapies in the clinical setting. Anti–growth factor receptor molecules and antiangiogenic drugs are considered.

FDA Report: Eculizumab (Soliris®) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

Andrew Dmytrijuk, Kathy Robie-Suh, Martin H. Cohen, Dwaine Rieves, Karen Weiss, Richard Pazdur
The Oncologist 2008; 13: 993-1000; doi:10.1634/theoncologist.2008-0086
[Abstract] [Full Text] [PDF]  

SUMMARY: Reported are the results of two studies of eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Eculizumab appears to be generally safe and effective for the treatment of paroxysmal nocturnal hemoglobinuria patients with transfusion-dependent hemolysis.

Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib

Mario E. Lacouture, Shenhong Wu, Caroline Robert, Michael B. Atkins, Heidi H. Kong, Joan Guitart, Claus Garbe, Axel Hauschild, Igor Puzanov, Doru T. Alexandrescu, Roger T. Anderson, Laura Wood, Janice P. Dutcher
The Oncologist 2008; 13: 1001-1011; doi:10.1634/theoncologist.2008-0131
[Abstract] [Full Text] [PDF]  

SUMMARY: Recommendations for the management of hand–foot skin reaction are provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with multikinase inhibitor therapy. These recommendations were developed by an international, interdisciplinary panel of experts who gathered in January 2008 to discuss and evaluate the best-practice management of these reactions.

Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial

Kerry S. Courneya, Lee W. Jones, Carolyn J. Peddle, Christopher M. Sellar, Tony Reiman, Anil A. Joy, Neil Chua, Linda Tkachuk, John R. Mackey
The Oncologist 2008; 13: 1012-1020; doi:10.1634/theoncologist.2008-0017
[Abstract] [Full Text] [PDF] [Supplemental Data]  

SUMMARY: The study reports results from the Exercise Training and Anemia trial comparing the effects of darbepoetin alfa alone with those of darbepoetin alfa plus aerobic exercise training on quality of life, fatigue, cardiorespiratory fitness, hemoglobin response, and drug dosing requirement in mild-to-moderately anemic cancer patients.

Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

Fairooz F. Kabbinavar, Joel F. Wallace, Eric Holmgren, Jing Yi, David Cella, Kathleen J. Yost, Herbert I. Hurwitz
The Oncologist 2008; 13: 1021-1029; doi:10.1634/theoncologist.2008-0003
[Abstract] [Full Text] [PDF]  

SUMMARY: This manuscript reports the results of the evaluation of changes in health-related quality of life associated with multiple administrations of bevacizumab combined with 5-fluorouracil–based chemotherapy in patients with metastatic colorectal cancer. The addition of bevacizumab to 5-fluorouracil-based chemotherapy improved time to disease progression and prolonged overall survival, without compromising patients' health-related quality of life.

Untreated Patients in "CT Screening for Lung Cancer: Update 2007"

Peter B. Bach
The Oncologist 2008; 13: 1030-1032; doi:10.1634/theoncologist.2008-0144
[Full Text] [PDF]  

SUMMARY: The author expresses concerns regarding possible errors in a recent article published in The Oncologist by the International Early Lung Cancer Action Project group.

In Reply

Claudia I. Henschke
The Oncologist 2008; 13: 1033; doi:10.1634/theoncologist.2008-9000
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.